Background: Cardiac involvement in Churg-Strauss vasculitis worsens the prognosis. Early detection is, therefore, warranted. Cardiac magnetic resonance (CMR) can visualize various forms of inflammatory changes in the myocardium. We tested whether CMR could elucidate cardiac damage in patients with biopsy-proven Churg-Strauss syndrome and clinical evidence of cardiac involvement.Methods and Results: Eleven patients underwent a CMR protocol including cine imaging for left ventricular function in long axes, T2-weighted imaging for edema detection, and contrast-enhanced T1-weighting for early and late gadolinium enhancement. CMR detected various form of myocardial injury in all patients. Systolic left ventricular function was impaired in 6 patients. Mean left ventricular ejection fraction was 45 +/- 15%. Left ventricular size was mildly enlarged (left ventricular end-diastolic volume index 94 +/- 23 mL/m(2)). Edema was present in 4 cases: 7 patients had pericardial effusion. Six patients had increased early contrast uptake. CMR detected late enhancement lesions in 9 of 11 patients, even in those with normal left ventricular size and function.Conclusions: CMR has the potential to detect myocardial injury in Churg-Strauss syndrome even when left ventricular function appears normal. (J Cardiac Fail 2008;14:856-860)

ObjectiveCardiac magnetic resonance imaging (CMR) has the potential to visualize various forms of transient and permanent myocardial damage in inflammatory diseases.We report on CMR in patients with clinical evidence of myocardial involvement in Churg-Strauss syndrome.In this vasculitis, inflammatory damage of small cardiac vessels can result in myocarditis and cardiomyopathy.

HomeHypertensionVol. 52, No. 6Cushing's Disease, Hypertension, and Other Sequels Free AccessCase ReportPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessCase ReportPDF/EPUBCushing's Disease, Hypertension, and Other Sequels Eugenia Singer, Sebastian Strohm, Ursula Göbel, Markus Bieringer, Dierk Schmidt, Wolfgang Schneider, Ralph Kettritz and Friedrich C. Luft Eugenia SingerEugenia Singer From the Medical Faculty of the Charité, Franz-Volhard Clinic, HELIOS Klinikum-Berlin, Berlin, Germany; and the Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine, Berlin, Germany. , Sebastian StrohmSebastian Strohm From the Medical Faculty of the Charité, Franz-Volhard Clinic, HELIOS Klinikum-Berlin, Berlin, Germany; and the Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine, Berlin, Germany. , Ursula GöbelUrsula Göbel From the Medical Faculty of the Charité, Franz-Volhard Clinic, HELIOS Klinikum-Berlin, Berlin, Germany; and the Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine, Berlin, Germany. , Markus BieringerMarkus Bieringer From the Medical Faculty of the Charité, Franz-Volhard Clinic, HELIOS Klinikum-Berlin, Berlin, Germany; and the Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine, Berlin, Germany. , Dierk SchmidtDierk Schmidt From the Medical Faculty of the Charité, Franz-Volhard Clinic, HELIOS Klinikum-Berlin, Berlin, Germany; and the Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine, Berlin, Germany. , Wolfgang SchneiderWolfgang Schneider From the Medical Faculty of the Charité, Franz-Volhard Clinic, HELIOS Klinikum-Berlin, Berlin, Germany; and the Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine, Berlin, Germany. , Ralph KettritzRalph Kettritz From the Medical Faculty of the Charité, Franz-Volhard Clinic, HELIOS Klinikum-Berlin, Berlin, Germany; and the Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine, Berlin, Germany. and Friedrich C. LuftFriedrich C. Luft From the Medical Faculty of the Charité, Franz-Volhard Clinic, HELIOS Klinikum-Berlin, Berlin, Germany; and the Experimental and Clinical Research Center, Max-Delbrück Center for Molecular Medicine, Berlin, Germany. Originally published3 Nov 2008https://doi.org/10.1161/HYPERTENSIONAHA.108.121640Hypertension. 2008;52:1001–1005Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: November 3, 2008: Previous Version 1 In his biography of Harvey Cushing, Michael Bliss1 discusses Cushing's perhaps most lasting scientific contribution as follows: "The old man's hunch had played out. After all those years of gathering information and misinformation about the pituitary, Cushing had correctly identified basophil pituitary adenomas as one significant cause of hypersecretion from the adrenal cortex.2 In those cases, Cushing's syndrome becomes Cushing's disease." In his report, which was actually a lecture at the Yale Medical School, Cushing mentioned, "painful adiposity, particularly of the trunk and chest, without involvement of the extremities, rounded shoulders, amenorrhea, purple colored striae on the abdomen, hypertension, a tendency toward spontaneous ecchymoses and epistaxis, rough, dry skin, blue and dusky in appearance, pressure headaches with low-grade chocked discs, fragility of the bones, and excessive growth of hair on the lips and elsewhere over the body."2 Cushing also observed that the tumors were too small to cause changes in the sella turcica that could be observed roentgenographically. Although Cushing's disease is not common, patients with the condition almost invariably are hypertensive, often severely so. Cushing mentioned all of the cardinal features, save for psychiatric manifestations; depression and even psychosis are also commonly present.3 Associated laboratory abnormalities include neutrophilic leukocytosis, hyperglycemia, hypokalemia, and hypercholesterolemia. Every medical student faithfully learns the above. Most have already observed the features of iatrogenic Cushing's syndrome as a sequel to long-term therapeutic glucocorticoid exposure. Faculty-attending physicians have all encountered Cushing's disease at some point in their careers and are, therefore, attuned. Nonetheless, when finally confronted, clinical reality often does not follow textbook rules. We recently encountered such a patient.Case Report (Eugenia Singer, Sebastian Strohm, Ursula Göbel, Markus Bieringer, Ralph Kettritz, and Friedrich C. Luft)The patient was a 51 year-old white man who had immigrated to Germany from the Czech republic. He was self-employed as a sculptor. He came to the emergency department because of progressive dyspnea and chest discomfort over 3 days. His blood pressure was 240/120 mm Hg, and his heart rate was irregularly irregular at 120 bpm. The ECG showed rapid atrial fibrillation, narrow QRS complexes, and inverted T waves in the precordial leads. His troponin T was elevated, which prompted his referral to our coronary care unit and cardiac catheterization laboratory. A brief history disclosed that the patient had received antihypertensive treatment for 2 years. He reported that his blood pressure readings were nonetheless high. Atrial fibrillation had also developed earlier, and cardioversion was performed a year before at another hospital. After atrial thrombi were excluded with transesophageal echocardiography, the patient was cardioverted and taken to the catheterization suite. Coronary angiography disclosed the presence of coronary plaques; however, all 3 of the major coronary vessels were open, and no evidence for an acute coronary syndrome was identified.The initial quantity of sodium was 143 mmol/L, potassium 2.7 mmol/L, chloride 99 mmol/L, and HCO3 31 mmol/L. The arterial pH was 7.53, Paco2 38 mm Hg, and Pao2 121 mm Hg with supplemental oxygen. The hemoglobin level was 16.7 g/dL, and the hematocrit level was 51 vol%. Urine electrolytes were obtained, and the transtubular potassium gradient (urine/plasma potassium divided by urine/plasma osmolality) was calculated at 14. In patients with hypokalemia, the kidney should avidly be retaining potassium, and a gradient <5 would be expected. The creatinine level was 97 μmol/L (<107 μmol/L), the urea level was 9.6 mmol/L (<8.3 mmol/L), and the glucose level was 8.3 mmol/L. A urinalysis was performed, which was normal. The physicians considered a secondary hypertension through a mineralocorticoid effect because of the metabolic alkalosis, hypokalemia, and hypernatremia. The active renin was 26 ng/L (1.5 to 18 ng/L), the serum aldosterone concentration was 218 ng/L (29 to 163 ng/L), and the 24 hour urinary aldosterone excretion was 11.2 μg/24 hours (3 to 19 μg/24 hours). The aldosterone:renin ratio was reported at 8.4 (<50). However, the adrenocorticotropic hormone (corticotropin [ACTH]) concentration was 22.2 pmol/L (<10.3 pmol/L), the serum cortisol was 1750 nmol/L (171 to 536 nmol/L), and the urine cortisol excretion was 18 774 nmol/d (100 to 379 nmol/d). The thyrotropin level was low at 0.16 mU/L (0.27 to 4.20 mU/L), the free T3 was 2.8 pmol/L (2.8 to 7.8 pmol/L), and the free T4 was 9.9 pmol/L (12.0 to 22.0 pmol/L). We performed low- (2 mg at bedtime) and high-dose (2 mg 4 times per day) dexamethasone suppression tests, but neither test resulted in cortisol suppression. After 2 mg of dexamethasone at bedtime, ACTH stayed at 26.0 pmol/L, and cortisol was still >1750 nmol/L. After 8 mg of dexamethasone, the values were still at 27.5 pmol/L for ACTH and remained >1750 nmol/L for cortisol.The patient had a generalized obesity. We examined him carefully for evidence of facial rounding, interscapular fat deposition, hirsutism, easy bruising, skin atrophy, purple striae, and proximal muscle weakness. However, we could not find any of these stigmata. We asked his wife to produce photographs of the patient from several years earlier. However, we could not discern any notable change in his appearance since that time, and his wife could not either. We considered the possibilities of Cushing's syndrome and Cushing's disease. Computed tomography (CT) of the head, chest, and abdomen disclosed no abnormalities. These studies were followed by MRI, and, again, no abnormalities were identified. Octreotide scintigraphy was performed that showed abnormal nuclide collection in the area of the pancreatic head. The possibility of a carcinoid tumor in that region was raised, although CT and MRI could not confirm this suspicion.During the hospitalization and workup, the patient was treated with torasemide (20 mg twice daily), amlodipine 10 mg, spironolactone 100 to 200 mg daily, ramipril 10 mg daily, aliskiren to 300 mg daily, candesartan 32 mg daily, and clonidine 0.3 mg twice daily. These medications were not all given concomitantly but in various combinations, and thereby reasonable (<140/90 mm Hg) blood pressure control was achieved. We next planned inferior petrosal sinus ACTH sampling in conjunction with corticotropin releasing hormone (CRH) stimulation. We discussed the nature of, and reasons for, the test with the patient in detail, and written, informed consent was obtained. On the following morning of the planned procedure, the patient climbed out of his fourth floor hospital room window and leaped to the concrete below. He was killed instantly. The medical examiner's office was contacted after the patient's death was ascertained.Clinical Discussion of Cushing's SyndromeThis patient and his tragic outcome bring to mind several important lessons. The "real world" deviates from textbooks. The presentation was that of acute heart failure, rapid atrial fibrillation, and the acute coronary syndrome with elevated troponin T values. This constellation calls for rapid response with acute cardioversion, treatment for pulmonary edema, and cardiac catheterization. Precisely, this cycle of events ensued. Cardioversion stabilized the patient, and his coronary arteries proved to be patent. There are numerous alternative explanations for elevated cardiac troponin levels, and sudden atrial fibrillation and cardiac failure serve to explain the findings.4 The patient had neither ST segment elevation nor ST segment depression; however, his inverted precordial T waves also facilitated his trip to the catheterization suite.The house staff physicians in the coronary care unit were very attuned to the patient's electrolyte disturbance on admission because of a similar patient we had several years ago with Cushing's syndrome from a small cell lung cancer (unpublished observations). They reacted quickly and obtained renin, aldosterone, cortisol, and ACTH values before in-hospital treatment for hypertension was begun. The elevated cortisol and ACTH concentrations drew their attention away from the diagnosis of primary aldosteronism, although aldosterone values in serum and urine were on the high side of normal in this patient. The active renin was 26 ng/L (1.5 to 18.0 ng/L). In most clinical circumstances, renin is estimated by assays of plasma renin activity (PRA). PRA is measured by generating angiotensin I from endogenous angiotensinogen followed by measurement of angiotensin I by radioimmunoassay. PRA measurements are convenient for estimating the biological activity of the system. They do of course not give information on the real concentration of active renin. A new method for measuring direct renin by an automated immunochemiluminometric assay was used in this patient. The assay uses 2 specific monoclonal antibodies. The first is biotin-labeled and captures renin by recognizing both active renin and prorenin. The second antibody is labeled with acridinium ester and can detect active renin and activated prorenin. The acridinium ester emits light on treatment with hydrogen peroxide. Reasonable correlations between this direct renin assay and PRA have been reported.5 In our hospital, the clinical laboratory made no announcement that they would no longer offer PRA but instead would report direct renin. Because our department is probably the sole "user," this new reporting mechanism resulted in some confusion. This confusion was compounded when medications, particularly aliskiren, were added. We assume that the elevated direct renin, which we would have predicted should have been low, was relatively high in this patient initially because of rapid atrial fibrillation, heart failure, treatment for pulmonary edema, and other confounders.Cushing's syndrome or disease became the working diagnosis early in this patient's hospital course. Irritating for us was the fact that the "classic" manifestations described in the textbook and literature, except for one, were not there. The house staff physicians were circumspect enough to obtain earlier photographs of the patient and to discuss with the spouse whether any morphological appearance changes had taken place. Central obesity was not present, although the patient was by no means thin. Facial rounding, interscapular fat deposition, hirsutism, easy bruising, skin atrophy, purple striae, and proximal muscle weakness were all conspicuous by their absence. The patient had type 2 diabetes mellitus, which is present in most patients with this level of obesity.We can only speculate on why our patient did not look like the patients who Harvey Cushing described. However, there is a rare genetic condition characterized by generalized, partial, target-tissue insensitivity to glucocorticoids. Charmandari et al6 recently reviewed the clinical aspects, molecular mechanisms, and implications of this disorder. They conducted a systematic review of the published, peer-reviewed medical literature. The clinical spectrum of primary generalized glucocorticoid resistance is broad and ranges from asymptomatic to severe cases of hyperandrogenism, fatigue, and/or mineralocorticoid excess. The molecular basis of the condition has been ascribed to mutations in the human glucocorticoid receptor gene, which impair glucocorticoid signal transduction and reduce tissue sensitivity to glucocorticoids. A consequent increase in the activity of the hypothalamic-pituitary-adrenal axis compensates for the reduced sensitivity of peripheral tissues to glucocorticoids at the expense of ACTH hypersecretion-related pathology.We measured urinary free cortisol and midnight plasma cortisol in saliva (data not shown), and we performed low- and high-dose dexamethasone suppression tests. All supported the diagnosis of Cushing's syndrome or disease. Once faced with the diagnosis, clinicians have to decide on the most likely source of Cushing's syndrome or disease. In our patient, the Cushing's was ACTH dependent. Thus, we were fairly certain that an adrenal adenoma or carcinoma was not responsible. CT imaging corroborated this opinion. We were left with the diagnosis of ACTH-dependent Cushing's syndrome (disease). We strongly considered the possibility of a corticotroph tumor in this patient.3 Such tumors can be very small and exceptionally difficult to detect.7,8 With imaging techniques, we moved down both arms of the diagnostic tree. CT and MRI were not helpful in terms of thoracic or abdominal studies. Studies of the brain gave no additional information. We ordered an octreotide scintigraphic scan of the abdomen and obtained a questionable result in the pancreas. Ectopic adrenocorticotrophic hormone syndromes from carcinoid tumors are well known. For instance, Fazel et al9 reported a patient with refractory hypertension and a 9-cm pancreatic mass that proved to be a neuroendocrine tumor. Extensive liver and mediastinal metastases were also found, and the patient had all of the clinical stigmata of Cushing's syndrome. She proved to have a carcinoid pancreatic tumor; however, a CT scan showed an obvious presence of the lesion in that patient. We were of course suspicious with the results of our octreotide imaging study but could not identify a substrate with either CT or MRI in the pancreas of our patient and, therefore, directed our attention elsewhere.Lindholm et al10 reported on the incidence and late prognosis of noniatrogenic Cushing's syndrome in Denmark. They retrieved data over an 11-year period and found that Cushing's disease was most common at 1.2 to 1.7 per million per year, whereas adrenal adenomas were less common at 0.6 per million per year and carcinomas fortunately even less common at 0.2 per million per year. Those patients had an extremely poor prognosis, whereas patients with Cushing's disease did fairly well, particularly those whose tumors were amenable to transsphenoidal neurosurgery. We directed our attention to that diagnosis and scheduled inferior petrosal sinus sampling.The vast majority (90% to 95%) of patients with ACTH-dependent Cushing's syndrome have a pituitary corticotroph microadenoma.11 We were concerned because our patient had prodigious hypercortisolism, hypokalemia, and an ACTH value that was fairly high. The octreotide scintigraphy gave us a positive result that we could not find with CT, MRI, or abdominal ultrasound. We elected to attempt pituitary imaging with MRI. Unfortunately, approximately half of corticotroph microadenomas causing Cushing's syndrome in adults are not visible with this technique.12 Our patient's MRI study was not informative. Inferior petrosal sinus ACTH sampling with CRH stimulation is the only study having the capacity to deliver a diagnostic sensitivity and specificity for Cushing's disease higher than the pretest probability.10 In the presence of documented hypercortisolism, an unequivocal pituitary ACTH gradient (inferior petrosal sinus:peripheral ACTH ratio) >2.0 in the basal state and >3.0 after CRH provides a diagnostic sensitivity of 100%.13 On the basis of these data, we scheduled our patient for the study.How Do ACTH and Glucocorticoids Cause Hypertension?Resistant hypertension was a significant comorbidity in our patient and interfered considerably with his workup. As our patient illustrates, hypertension in Cushing's syndrome is almost invariably present and can be severe. Nagai et al14 presented a patient with malignant hypertension from Cushing's disease, who had features similar to our patient. Their patient had blood pressure values of 290/160 mm Hg without treatment. The patient also had no classical stigmata of Cushing's syndrome, aside from an elevated blood sugar. PRA was not maximally suppressed in their patient, and the serum aldosterone concentration was 11 pg/mL. Cortisol and ACTH levels were high and could not be suppressed. Pituitary imaging revealed a tumor that was removed, after which the hypertension and the diabetes resolved. The authors pointed out that the pressor responses to norepinephrine and angiotensin II are increased in patients with Cushing's syndrome.14The association between glucocorticoid excess and hypertension is complex and still poorly understood. Hypothesized mechanisms include increased hepatic angiotensinogen synthesis, central regulation of baroreflex function and sympathetic tone, inhibition of vasodilator and stimulation of vasoconstrictor systems in vascular tissue, enhanced glucocorticoid-mediated vascular reactivity to norepinephrine, effects on sodium and volume homeostasis, and increase of local endothelial growth factor activity.15 A role for local glucocorticoid reamplification in obesity and the metabolic syndrome has been suggested. The enzyme 11 β-hydroxysteroid dehydrogenase (11 β-HSD)-1 regenerates active cortisol from inactive 11-keto forms, and mice with transgenic overexpression of 11 β-HSD-1 in fat cells develop visceral obesity with insulin resistance and dyslipidemia. Masuzaki et al16 recently reported that these mice also have high blood pressure. Glucocorticoids are known to increase plasma angiotensinogen concentrations.17 In the absence of renin suppression, as was the case in our patient, considerable amounts of angiotensin II could be generated. Furthermore, ACTH can result in aldosterone release; aldosterone was also elevated in our patient.18 Glucocorticoids also act within the brain to regulate the baroreflex function and thereby influence sympathetic tone.19The mineralocorticoid receptor could also have contributed to hypertension in our patient. In cases of cortisol excess, the main agonist of the receptor may be cortisol rather than aldosterone. The enzyme 11 β-HSD-2 converts cortisol to cortisone in the distal nephron to protect the mineralocorticoid receptor from the agonist cortisol; however, the enzyme is not 100% efficient. 11 β-HSD-2 activity in vascular tissue, the heart, and the central nervous system is uncertain.20 Our group recently demonstrated glucocorticoid-related signaling effects in vascular smooth muscle cells.21 We identified new mineralocorticoid receptor-dependent signaling pathways and suggested that glucocorticoids may contribute to vascular disease via mineralocorticoid receptor signaling, independent of circulating aldosterone. ACTH may decrease 11 β-HSD-2 and, thus, amplify the actions of cortisol on the mineralocorticoid receptor.22 Furthermore, glucocorticoid β-hydroxylation, which induces urinary sodium retention, is increased in patients with Cushing's syndrome.23 Our patient had ample sodium retention. While residing in our intensive care unit, large amounts of sodium chloride-containing solutions were infused, in part because of an episode of local bleeding at the site of a femoral puncture for cardiac catheterization. Thus, mineralocorticoid action would appear to play a role in our patient's hypertension, although spironolactone 200 mg/d had little apparent blood pressure-reducing effect in our patient.The sodium pump possibly contributed to hypertension in our patient. The Na,K-ATPase contains a binding site for cardiac glycosides, such as ouabain, digoxin, and digitoxin, which is highly conserved among species. Dostanic-Larson et al24 showed recently that this site plays an important role in the regulation of blood pressure and that it specifically mediates ACTH-induced hypertension. They used genetically engineered mice in which the Na,K-ATPase α2 isoform, which is normally sensitive to cardiac glycosides, was made resistant to these compounds. Chronic administration of ACTH caused hypertension in wild-type mice but not in mice with a ouabain-resistant α2 isoform of Na,K-ATPase. Their results demonstrate that the cardiac glycoside binding site of the Na,K-ATPase-α isoforms have a physiological function. When overstimulated after high ACTH, as was the case in our patient, the Na,K-ATPase should serve for avid sodium reabsorption and could contribute to salt-sensitive hypertension. Evidence exists that the adrenal gland may be the source for endogenous glycosides in response to ACTH that regulate the sodium pump. Inhibition of the Na,K-ATPase raises intracellular sodium, which reverses the transport mode of the Na/Ca exchanger. The resultant influx of calcium could contribute to increased vascular smooth muscle cell tone.Cushing's Syndrome and Psychiatric IllnessWhere we failed was in recognizing our patient's psychiatric illness and in not taking the proper precautions. German hospitals are, as a rule, not air conditioned, except for intensive care units and operating rooms. Wide windows that can be opened, even on upper stories, are nothing uncommon. Medical students learn that depression is a part of the Cushing's syndrome complex, and that fact did not escape us. The chief of service, who saw this patient several times, recalls having wondered about the patient's "flattened" affect. However, we failed to act, and no suicide precautions were initiated and no psychiatric consultation was obtained.Decades ago, patients with depression were observed to exhibit hypersecretion of both cortisol and its metabolites.25 The observation that patients with Cushing's disease or syndrome commonly experienced severe depression and anxiety and the increased production and secretion of glucocorticoids, such as cortisol, in healthy people exposed to stress contributed to the modern stress-diathesis hypothesis of depression in which excess secretion of cortisol is thought to play a significant pathophysiological role in the etiology of depression.26 The CRH receptor has become a drug target that could play a role in the treatment of depression.27 Investigations of CRH type 1 receptor nonapeptide antagonists suggest therapeutic potential for treatment of these and other neuropsychiatric diseases. Cushing's disease and related pituitary/adrenal disorders could become obvious applications for CRH type 1 receptor antagonists. For overt psychosis, which our patient may have had, heroic measures are sometimes used. Bilgin et al28 reported on the use of etomidate, which blocks the cortisol synthesis, and mifepristone, which competes with cortisol for binding to cortisol receptors to manage a severe psychosis in a patient with Cushing's syndrome from adrenal carcinoma.Pathological Report (Dierk Schmidt and Wolfgang Schneider)The medical examiners determined that the patient died of injuries resulting from his fall. They were not interested in his medical problems, and their examination was conducted in a more leisurely fashion, some days after his death. Thus, the pituitary was not placed into formalin immediately, and paraffin embedding was necessarily delayed. This state-of-affairs made the pathologist's work substantially more difficult and also limited the studies that could be performed. The pancreas was inspected and not found to contain a tumor.The histological picture of the anterior pituitary was one of primary ACTH cell hyperplasia. The hyperplasia was predominantly nodular, and the acinar structures were not disrupted. However, the reticular pattern showed clear evidence of expansion. We performed ACTH immunohistochemistry staining (Figure, panel A). Ample numbers of ACTH (red) staining cells were identified, within a retained acinar structure. The ACTH-staining cells were observed to invade the neurohypophysis. This invasion was confirmed with periodic acid Schiff staining (Figure, panel B). Download figureDownload PowerPointFigure. Gomori stain. A, ACTH immunohistochemistry staining of hyperplastic basophilic cells in adenohypophysis. B, Invasion of basophilic cells into the neurohypophysis. Periodic acid Schiff staining.Primary ACTH cell hyperplasia may result from excessive secretion of CRH or may be idiopathic.29–31 The hyperplasia is predominantly nodular but may be diffuse if CRH is stimulated. Patients with excess CRH production from ectopic sources such as neoplasms or gangliocytic hamartomas may present with Cushing's syndrome, eg, from small cell lung cancer. In such cases, a full-blown picture of Cushing's syndrome is not present because of the rapid course of the disease. Unfortunately, CRH was not measured in this patient. In pituitary hyperplasia because of ectopic hormone production, the adrenal glands may become markedly enlarged. In our patient, the glands were "plump" with imaging but were not markedly enlarged. Unfortunately, a precise assessment of the adrenal glands was not possible, because the medical examiners did not place this tissue at our disposal. ACTH cell hyperplasia may be difficult to diagnose in small biopsy specimens because of the variable pattern and distribution of ACTH cells in the normal pituitary. Ours was not a surgical specimen; however, the pituitary was removed under less-than-ideal conditions. Samples from the pars nervosa may show ACTH-positive cell invasion, as was the case in our patient. Purists could argue that our diagnosis is not proven without doubt; however, we believe our clinical arguments, and the histology that we do have are compelling.Pathological DiagnosisWe diagnosed pituitary hyperplasia with ACTH production.DisclosuresNone.FootnotesCorrespondence to Friedrich C. Luft, Experimental and Clinical Research Center, Building 84, Max Delbrück Center, Robert-Rössle Str 10, 13125 Berlin, Germany. E-mail: [email protected] References 1 Bliss M. Harvey Cushing A Life in Surgery. New York, NY: Oxford University Press, Inc; 2005: 477–478.Google Scholar2 Cushing H. A new pituitary syndrome. N Engl J Med. 1932; 206: 643.Google Scholar3 Newell-Price J, Bertagna X, Grossman AB, Nieman LK. Cushing's syndrome. Lancet. 2006; 367: 1605–1617.CrossrefMedlineGoogle Scholar4 Jeremias A, Gibson CM. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med. 2005; 142: 786–791.CrossrefMedlineGoogle Scholar5 Hartman D, Sagnella GA, Chesters CA, MacGregor GA. Direct renin assay and plama renin activity assay compared. Clin Chem. 2004; 50: 2159–2161.CrossrefMedlineGoogle Scholar6 Charmandari E, Kino T, Ichijo T, Chrousos GP. Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder. J Clin Endocrinol Metab. 2008; 93: 1563–1572.CrossrefMedlineGoogle Scholar7 Woo YS, Isidoria AM, Wat WZ, Kaltsas GA, Afshar R, Sagin I, Jenkins PJ, Monson JP, Besser GM, Grossman AB. Clinical and biochemical characteristics of adrenocorticotropin-secreting macroadenomas. J Clin Endocrinol Metab. 2005; 90: 4963–4969.CrossrefMedlineGoogle Scholar8 Bahurel-Barrera H, Assie G, Silvera S, Bertagna X, Coste J, Legmann P. Inter- and intra-observer variability in detection and progression assessment with MRI of microadenoma in Cushing's disease patients followed up after bilateral adrenalectomy. Pituitary. 2008; 11: 263–269.CrossrefMedlineGoogle Scholar9 Fazel P, Ganesa P, Mennel RG, Austin NA. The ectopic adrenocorticotropic hormone syndrome in carcinoid tumors. Proc (Bayl Univ Med Cent). 2008; 21: 140–143.CrossrefMedlineGoogle Scholar10 Lindholm J, Juul S, Jorgensen OL, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz K, Kristensen LO, Laurberg P, Schmidt K, Weeke J. Incidence and late prognosis of Cushing's syndrome: a population-based study. J Clin Endocrinol Metab. 2001; 86: 117–123.MedlineGoogle Scholar11 Findling JW, Raff H. Cushing's syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab. 2006; 91: 3746–3753.CrossrefMedlineGoogle Scholar12 Tabarin A, Laurent F, Catargi B, Olivier-Puel F, Lescene R, Berge J, Galli FS, Drouillard J, Roger P, Guerin J. Comparative evaluation of conventional and dynamic magnetic resonance imaging of the pituitary gland for the diagnosis of Cushing's disease. Clin Endocrinol (Oxf). 1998; 49: 293–300.CrossrefMedlineGoogle Scholar13 Saruta T, Suzuki H, Handa M, Igarashi Y, Kondo K, Senba S. Multiple factors Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DI, Katz DA, Cutler GB, Loriaux DL. Petrosal sinus sampling with and without corticotrophin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med. 1991;325:897–905.Google Scholar14 Nagai T, Imamura M, Misumi S, Mori M. Subclinical Cushing's disease accompanied by malignant hypertension and diabetes mellitus. Intern Med. 2002; 41: 566–570.CrossrefMedlineGoogle Scholar15 Gomez-Sanchez CE, Gomez-Sanchez EP, Yamakita N. Endocrine causes of hypertension. Semin Nephrol. 1995; 15: 106–115.MedlineGoogle Scholar16 Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, Flier JS. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest. 2003; 112: 83–90.CrossrefMedlineGoogle Scholar17 Reid IA. Effect of angiotensin II and glucocorticoids on plasma angiotensinogen concentration in the dog. Am J Physiol. 1977; 232: E234–E236.MedlineGoogle Scholar18 Kem DC, Weinberger MH, Gomez-Sanchez C, Higgins JR, Kramer NJ. The role of ACTH in the episodic release of aldosterone in patients with idiopathic adrenal hyperplasia, hypertension, and hyperaldosteronism. J Lab Clin Med. 1976; 88: 261–270.MedlineGoogle Scholar19 Bechtold AG, Scheuer DA. Glucocorticoids act in the dorsal hindbrain to modulate baroreflex control of heart rate. Am J Physiol Regul Integr Comp Physiol. 2006; 290: R1003–R1011.CrossrefMedlineGoogle Scholar20 Funder J, Myles K. Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology. 1996; 137: 5264–5268.CrossrefMedlineGoogle Scholar21 Molnar GA, Lindschau C, Dubrovska G, Mertens PR, Kirsch T, Quinkler M, Gollasch M, Wresche S, Luft FC, Muller DN, Fiebeler A. Glucocorticoid-related signaling effects in vascular smooth muscle cells. Hypertension. 2008; 5: 1372–1378.Google Scholar22 Saruta T, Suzuki H, Handa M, Igarashi Y, Kondo K, Senba S. Multiple factors contribute to the pathogenesis of hypertension in Cushing's syndrome. J Clin Endocrinol Metab. 1986; 62: 275–279.CrossrefMedlineGoogle Scholar23 Clore J, Schoolwerth A, Watlington CO. When is cortisol a mineralocortocoid? Kidney Int. 1992; 42: 1297–1308.CrossrefMedlineGoogle Scholar24 Dostanic-Larson I, Van Huysse JW, Lorenz JN, Lingrel JB. The highly conserved cardiac glycoside binding site of Na,K-ATPase plays a role in blood pressure regulation. Proc Natl Acad Sci U S A. 2005; 102: 15723–15724.CrossrefMedlineGoogle Scholar25 Carpenter W, Bunney W. Adrenal cortical activity in depressive illness. Am J Psychiatry. 1971; 128: 289–298.Google Scholar26 Gillespie CF, Nemeroff CB. Hypercortisolemia and depression. Psychosom Med. 2005; 67 (suppl 1): 526–528.Google Scholar27 Contoregi C, Rice KC, Chrousos G. Nonpeptide corticotropin-releasing hormone receptor type 1 antagonists and their applications in psychosomatic disorders. Neuroendocrinology. 2004; 80: 111–123.CrossrefMedlineGoogle Scholar28 Bilgin YM, van der Wiel HE, Fischer HR, De Herder WW. Treatment of severe psychosis due to ectopic Cushing's syndrome. J Endocrinol Invest. 2007; 30: 776–779.CrossrefMedlineGoogle Scholar29 Horvath E, Kovacs K. Ultrastructural diagnosis of pituitary adenomas and hyperplasias. In Lloyd RV, ed. Surgical Pathology of the Pituitary Gland. Philadelphia, PA: WB Saunders; 1993: 52–84.Google Scholar30 Lloyd RV, Chandler WF, McKeever PE, Schteingart DE. The spectrum of ACTH-producing pituitary lesions. Am J Surg Pathol. 1986; 10: 618–626.CrossrefMedlineGoogle Scholar31 McKeever PE, Koppelman MC, Metcalf D, Quindlen E, Kornblith PL, Strott CA, Howard R, Smith BH. Refractory Cushing's disease caused by multinodular, ACTH-cell hyperplasia. J Neuropathol Exp Neurol. 1982; 41: 490–499.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Priya G, Chhabra S and Kalra S (2021) Rhythm Disorders in Endocrinology, European Journal of Arrhythmia & Electrophysiology, 10.17925/EJAE.2021.7.1.12, 7:1, (12), . Pivonello R, De Martino M, De Leo M, Simeoli C and Colao A (2016) Cushing's disease: the burden of illness, Endocrine, 10.1007/s12020-016-0984-8, 56:1, (10-18), Online publication date: 1-Apr-2017. December 2008Vol 52, Issue 6 Advertisement Article InformationMetrics https://doi.org/10.1161/HYPERTENSIONAHA.108.121640PMID: 18981320 Manuscript receivedAugust 17, 2008Manuscript acceptedOctober 8, 2008Originally publishedNovember 3, 2008Manuscript revisedSeptember 17, 2008 PDF download Advertisement SubjectsClinical StudiesTreatment

BACKGROUND A subset of patients with Wegener's granulomatosis does not respond to daily oral cyclophosphamide (CYC) plus corticosteroids or suffers from intolerable side effects. A 6 month course of the immunosuppressant 15-deoxyspergualin (DSG) has previously been employed successfully in these refractory cases. However, there are no reports on long-term treatment with DSG. METHODS To document the effects of prolonged DSG treatment, this study reports on seven patients suffering refractory Wegener's granulomatosis, who were successfully treated with DSG over an average of 26.5 months (range: 11-55.5 months). RESULTS Before administration of DSG, patients had experienced an average of 6.6 relapses (range: 3-12) under an average of 5.4 (range: 2-11) different therapeutic approaches, which included CYC in all cases. All suffered active disease when DSG was initiated. Four were unresponsive to CYC and three did not tolerate it. DSG (0.5 mg/kg/day subcutaneous) was given for 2-3 weeks until the leukocyte count dropped to 3000/microl, followed by a rest until a leukocyte count of 4000/microl was reached again. No other immunosuppressants besides corticosteroids were given. All patients showed a long-lasting, favourable response to DSG with complete (n = 5) or partial (n = 2) remission. Only one case relapsed while being treated with DSG. Termination/interruption of DSG was followed by relapse in four of five occasions. Resumption of DSG led to complete remission. Currently, five of the seven patients are still treated with DSG and are in remission. Infections, mainly of the respiratory tract, were observed in five cases and resolved after treatment. One case developed a third-degree heart block that required pacing. CONCLUSIONS In patients with refractory Wegener's granulomatosis, prolonged treatment with DSG seems safe and successful.

A 40 year-old woman was admitted because of profound weakness for the past 4 days. She also claimed to have a severe headache for which she had ingested large doses ( 8 g) of aspirin. She steadfastly denied nausea or vomiting and did not complain of abdominal pain. Past medical history revealed generous alcohol consumption and a cardiomyopathy, ostensibly alcohol induced. She had intermittent atrial fibrillation for which she received phenprocoumon; however, her most recent ejection fraction was 48%. On physical examination, her temperature was 38 C, her heart rate was regular at 84 beats/min, her respiratory rate was 20/min, and her blood pressure was 80/60mmHg. The blood pressure did not fall with upright posture. The neck veins were not distended, the chest was clear, the heart was not appreciably enlarged, and the abdomen was not tender. Bowel sounds were diminished but present. The liver was enlarged at 3 cm below the right costalmargin.Therewasnoperipheral oedema. Her haemoglobin was 11.4 g/dl, and the haematocrit was 36 vol%. The leukocyte count was 11 400/mm, the INR was 8.4, and C-reactive protein (CRP) was 280mg/l. Plasma sodium was 132, chloride 87, potassium 5.5, magnesium 1.49, total calcium 1.49 and phosphorus 7.76 (all mmol/l). Plasma creatinine was 1290 mmol/l, urea 66mmol/l, lipase 131U/l, amylase 94U/l, aspartate aminotransferase U/l, alanine aminotransferase 42U/l, g-glutamyl transferase 150U/l, total protein 63 g/l and albumin 23 g/l. The urine showed granular casts, erythrocytes and leukocytes with protein þ1 without ketones. The urine osmolality was 335mOsm/kg H2O, Na <10mmol/l, Cl <10mmol/l and K 44mmol/l. The urine creatinine was 17mmol/l and urea 112mmol/l. The fractional excretion of Na was <1% and that of urea was 13%. Arterial blood disclosed pH 7.24, PaCO2 29mmHg, PaO2 105 mmHg, HCO3 12mmol/l and lactate 0.75mmol/l. Toxicological studies revealed a plasma salicylate level of 49mg/dl, while ethanol, methanol and ethylene glycol were undetectable. The electrocardiogram was unremarkable with the exception of a prolonged QT interval attributable to a lengthened ST segment (Figure 1, top). An abdominal ultrasound disclosed an enlarged liver of increased density. The kidneys were normal in size without obstruction. No free abdominal fluid was detected. We then measured creatinine kinase and myoglobin. Both were only slightly elevated. Plasma parathyroid hormone and 25-OH-vitamin D levels were within the low-normal range. We were confronted with a patient who presumably had pre-renal failure, anion gap metabolic acidosis, hypocalcaemia and profound hyperphosphataemia of unknown cause. We did not believe that her salicylate level explained the anion gap, the calcium or the phosphate levels. At the time, we felt we could not rule out a tumour-lysis syndrome and therefore acute haemodialysis coupled with volume expansion was performed. Three dialyses were done on three consecutive days. Thereafter, she had gained 5 kg in weight, her calcium increased to 2.31 and her phosphorus decreased to 1.1mmol/l. Her electrocardiogram (Figure 1, bottom) now showed a normal QT interval. Her CRP decreased to 145mg/l. She continued to deny abdominal pain. In the process of pursuing the idea of an occult neoplasm, a magnetic resonance imaging (MRI) study of the abdomen was carried out (Figure 2). Because of the patient’s acute renal failure, we did not perform computed tomography (CT) with contrast agents. To our considerable irritation and surprise, the MRI scan showed clear evidence of acute pancreatitis with secondary haemorrhage. The aetiology of the hypocalcaemia, the hyperphosphataemia and the pre-renal azotaemia suddenly became clear. Less obvious was why her acute pancreatitis failed to present with pain and enzyme elevations. We initially thought that a massive acute phosphate load might have caused hyperphosphataemia in our patient. Since exogenous causes, such as phosphate-containing enemas, could Correspondence and offprint requests to: Andreas Birkenfeld, Franz Volhard Clinic, Wiltberg Strasse 50, D-13125 Berlin, Germany. Email: birkenfeld@fik.charite-buch.de

The combination of cyclophosphamide (CYC) and oral corticosteroids is effective in the majority of patients with antineutrophil cytoplasmic antibody-associated vasculitis (AASV), but it carries substantial risk of drug-related morbidity and mortality. New regimens are desired, especially in refractory cases. The immunosuppressant 15-deoxyspergualin (DSG) is effective in experimental autoimmune disease and transplantation as well as in acute kidney transplant rejection in humans. To assess the efficacy and safety of DSG, an open label multicenter trial was conducted in patients with AASV who were either unresponsive or had contraindications for standard immunosuppressants. Included were 19 cases of Wegener granulomatosis and one case of microscopic polyangiitis. Nine of them had received CYC shortly before study entry without apparent therapeutic success. DSG (0.5 mg/kg per d) was given for 2 to 3 wk until the WBC count dropped to 3000/ micro l followed by a rest until at least a WBC of 4000/ micro l was reached again. This was repeated up to six cycles. During the study, no other immunosuppressants besides steroids were allowed. Disease improvement during treatment with DSG was achieved in 70% of cases (six cases of complete remission; eight cases of partial remission). Leucopenia occurred in each patient in a regular pattern during the cycles and was transient without exception. No mortality or septicemia was observed. Mild to moderate infections mainly in the respiratory tract were observed but resolved under adequate treatment without sequel. It is concluded that treatment with DSG is successful in patients with refractory Wegener granulomatosis under careful monitoring of WBC count.

therapy 53 Adverse events 455 -reactions 455 AIDS 332 Allograft rupture 71 Alloimmune hemolysis 473 Ammonium chloride 74 Amyloidosis 68 Anemia 27, 89 Angiotensin II 373 Angiotensin-converting enzyme inhibitors 149, 268 Anion gap 369 Ankle-arm blood pressure index 107 Anticardiolipin antibodies 351 Antilactoferrin antibody 57 Antineutrophil cytoplasmic antibody 57 Antiretroviral therapy 332 Aorto-iliac atherosclerosis 487 Arterial blood gas values 319 Aspergillus 329 AST-120 232 Atheroembolization 263 Atherosclerosis 107, 487 Axillo-femoral bypass 487 Basement membrane 175 Behçet disease 68, 217 Bidialysis 429 Big men 429 Bioelectrical impedance analysis 311 Biological markers 48 Blood pressure 193 Body mass index 169 Bone markers 283 -turnover

Key words: autosomal dominant polycystic kidney followed, as shown in Figure 1. This examination revealed similar changes. A selective renal arteriogram disease; clear-cell renal-cell carcinoma; urinary tract infection is shown in Figure 2, which shows several abnormal polar vessels supplying the upper pole mass. Involvement of the renal vein by tumour could not be shown. An ultrasound-guided biopsy specimen Case report revealed typical changes of a clear-cell renal-cell carcin-oma (RCC). The right kidney was carefully visualized with the imaging studies, but revealed no suspicious A 72-year-old woman with known, stable, renal lesions. Additional work-up failed to show any evid-insufficiency was admitted because of fever, malaise, ence of distant metastasis and the patient recovered and dysuria, which began 48 h prior to admission. She from her urinary tract infection uneventfully, although had known autosomal dominant polycystic kidney her creatinine concentration remained at 348 mmol/l. disease (ADPKD) and several family members had developed end-stage renal disease. She had previously had urinary tract infections which had responded to Discussion antibiotics. Her creatinine had exceeded 200 mmol/l a year prior to admission and was gradually increasing. Modern imaging techniques not uncommonly confront On physical examination she was moderately febrile physicians with disturbing findings in asymptomatic (38°C), but not in acute distress. She had mild back patients. The term 'incidentaloma' is generally applied and abdominal tenderness. The kidneys and the liver to accidentally located adrenal masses; however, the were easily palpable and exhibited gross, nodular struc-term appears appropriate here. Our patient with tures consistent with ADPKD. The urinalysis showed ADPKD had developed RCC, which we carefully and many leukocytes and bacteria. Her serum creatinine zealously documented. Her actual reason for coming concentration was 351 mmol/l. A urine culture yielded to the hospital had resolved and she wanted to go Klebsiella sp. and ciprofloxacin was administered with home. We were confronted with serious medical good response. decisions in this case of an elderly woman with An ultrasound examination revealed cystic changes ADPKD-induced chronic renal failure, who was other-in both kidneys and the liver, as well as a denser wise doing relatively well. structure in the upper pole of the left kidney, prompting The association of RCC and ADPKD is controver-the computerized tomographic study shown in sial; an increased incidence has not been clearly shown. Figure 1. A large, dense structure with a single cavity Zeier et al. [1] could find no evidence for an increase can …

We describe a patient with Wegener's granulomatosis whose disease presented as pseudotumor of the orbit and a breast mass. Both findings were misinterpreted and errors in diagnosis resulted, despite the availability of rapid and accurate diagnostic tests for this disease. We report this case to emphasize the more unusual presentations of Wegener's granulomatosis.